Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
NCT04485793 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2024-01-31
Summary
The joint ESC/EAS guidelines for the management of dyslipidaemias recommend, for patients at low/moderate CV risk with raised LDL-C, a set of measures collectively defined as "lifestyle interventions", with use of drugs only if the LDL-C levels cannot be controlled with such lifestyle interventions. "Lifestyle interventions" also includes food supplements. The reason is the following: a simple "dietary advice" has been shown (Cochrane review and meta-analysis, Rees et al, 2013) to achieve a modest reduction of total-C and LDL-C. The review reports: Dietary advice reduced total serum cholesterol by 0.15 mmol/L (95% CI 0.06 to 0.23) and LDL cholesterol by 0.16 mmol/L (95% CI 0.08 to 0.24) after 3 to 24 months." An average reduction of LDL-C by 0.16 mmol/L (6.2 mg/dL) is definitely insufficient to control the level of LDL-C in those subjects. Therefore, those subjects would lose motivation to keep dieting. In this context, use of supplements would significantly amplify the result of diet.
A significant proportion of ischemic cardiovascular events are believed to be supported by the coexistence of traditional cardiovascular risk factors such as diabetes, hypertension, dyslipidemia, smoking, and others. The aggregation of these factors is accompanied by a significant increase in the risk of cardiovascular events.
Observational studies shown the existence of a relationship between cholesterolemia and coronary heart disease, clearly showing that subjects with even modestly increased total cholesterol values over time develop both fatal and non-fatal vascular events with a higher frequency compared to subjects with similar characteristics, but with lower basal values of cholesterol.
Numerous controlled intervention studies, on the other hand, have shown that there is a close correlation between cholesterol reduction and cardiovascular risk; in fact, reductions in the plasma concentration of total and LDL-C, obtained through lifestyle modification or specific drugs, result in reductions in the incidence of major coronary events. The effectiveness of these interventions has been demonstrated both in subjects in primary prevention and in patients in secondary prevention.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
Dietary supplement
Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM). Oral administration: 1 tablet/day at evening meal
- OTHER
-
Placebo
Oral administration: 1 tablet/day at evening meal
Sponsors & Collaborators
-
University of Bologna
lead OTHER
Principal Investigators
-
Claudio Borghi, MD · S. Orsola-Malpighi University Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-09-21
- Primary Completion
- 2021-10-04
- Completion
- 2021-10-04
Countries
- Italy
Study Locations
More Related Trials
-
Dose Effect of Limicol on (LDL)-Cholesterol Levels
NCT01354340 ·Status: COMPLETED ·Phase: NA
-
The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia
NCT01645046 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome
NCT00659321 ·Status: COMPLETED ·Phase: PHASE3
-
the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C
NCT06132360 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Red Yeast Rice, Phytosterols and L-tyrosol on Lipid Profile and Endothelial Function
NCT03065491 ·Status: COMPLETED ·Phase: NA
-
Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol
NCT00143663 ·Status: COMPLETED ·Phase: PHASE3
-
Dose Ranging Study of the Effects of Alpha Lipoic Acid on Oxidative Stress
NCT00857376 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
NCT00404001 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels
NCT02187757 ·Status: COMPLETED ·Phase: PHASE3
-
Combined Effects of Bioactive Compounds in Lipid Profile
NCT01562080 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety Study of BMS-844421 for Treatment of Hypercholesterolemia
NCT01082562 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)
NCT01436253 ·Status: COMPLETED
-
Efficacy and Tolerability of the Nutraceutical Formulation Coleosoma in Dyslipidemic Subjects
NCT03027336 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Arterin Cholesterol for Reduction of Lipid Levels
NCT04749784 ·Status: UNKNOWN ·Phase: NA
-
Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being
NCT02255682 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides
NCT00562575 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Armolipid Plus on Cholesterol Levels and Endothelial Function
NCT00654459 ·Status: COMPLETED
-
Effect of LIMICOL®-NG on Plasma LDL-cholesterol Concentration in Subjects with Moderate Hypercholesterolemia
NCT06894251 ·Status: RECRUITING ·Phase: NA
-
Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion
NCT04314167 ·Status: TERMINATED ·Phase: NA
-
LIFESTAT - Living With Statins, a Cross Sectional Study
NCT02250677 ·Status: COMPLETED
-
Nutraceuticals to Improve Lipid Profile in European Countries
NCT01649986 ·Status: UNKNOWN ·Phase: PHASE4
-
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
NCT02087917 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.
NCT00251680 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers
NCT06758661 ·Status: COMPLETED ·Phase: PHASE1
-
Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia
NCT00293878 ·Status: COMPLETED ·Phase: PHASE2